Meeting
2017 ASCO Annual Meeting
Phase 3, randomized, double-blind, placebo-controlled study of venetoclax combined with azacitidine versus azacitidine in treatment-naïve patients with acute myeloid leukemia.
Authors
Jalaja Potluri
AbbVie Inc., Chicago, IL
Jalaja Potluri , Tu Xu , Wan-Jen Hong , Mack H. Mabry
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT02993523
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS7069)
DOI
10.1200/JCO.2017.35.15_suppl.TPS7069
Abstract #
TPS7069
Poster Bd #
267b
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
First Author: Shaji Kumar
Poster
2017 ASCO Annual Meeting
CASCADE: A phase 3, randomized, double-blind study of vadastuximab talirine (33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML).
First Author: Eunice S. Wang
Poster
2023 ASCO Annual Meeting
SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.
First Author: Mark Andrew Dickson
Poster
2022 ASCO Annual Meeting
MOTION: A randomized, phase 3, placebo-controlled, double-blind study of vimseltinib (DCC-3014) for the treatment of tenosynovial giant cell tumor.
First Author: William D. Tap